Oct 8 (Reuters) - GlaxoSmithKline Plc is recalling
its heartburn medicine Zantac as a "precautionary measure" due
to a probable cancer-causing impurity in the drug, Britain's
medicines watchdog said on Tuesday.
GSK is recalling all unexpired stock of Zantac, also sold
generically as ranitidine, from pharmacies as a precaution due
to possible contamination with an impurity NDMA, which has
genotoxic and carcinogenic potential, the Medicines and
Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zantac-injection-50mg-2ml-zantac-syrup-150mg-10ml-zantac-tablets-150mg-zantac-tablets-300mg-el-19-a-24.
(Reporting by Justin George Varghese in Bengaluru; editing by
Bill Berkrot)
Glaxosmithkline (GSK)